Skip to main content
. Author manuscript; available in PMC: 2020 Jun 15.
Published in final edited form as: Lancet Glob Health. 2020 Mar;8(3):e440–e450. doi: 10.1016/S2214-109X(20)30003-6

Figure 5.

Figure 5.

Univariate sensitivity analysis on total costs for Scenario S4. Implementing a simplified treatment pathway as in X5 includes fewer visits and laboratory investigations. Details are in Supplementary Materials. DAA: direct-acting antiviral; Ab: antibody; PCR: polymerase chain reaction; CC: compensated cirrhosis; DC: decompensated cirrhosis; HCC: hepatocellular carcinoma; LTFU: lost-to-follow-up; Tx: treatment.